Value of ultrasound-assessed dactylitis in the early diagnosis of psoriatic arthritis
- PMID: 39729651
- DOI: 10.1016/j.semarthrit.2024.152612
Value of ultrasound-assessed dactylitis in the early diagnosis of psoriatic arthritis
Abstract
Purpose: The primary objective of this prospective, longitudinal, observational, single-centre study was to evaluate the association between ultrasound-assessed lesions of dactylitis and the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis (PsO) and hand arthralgia.
Methods: We included adult patients diagnosed with PsO with hand arthralgia, with or without other musculoskeletal complaints. They were clinically assessed at baseline, 6 and 12 months by a rheumatologist blinded to the ultrasound findings. At baseline, patients underwent a B-mode (BM) and power Doppler (PD) ultrasound assessment by other rheumatologist blinded to clinical data. The ultrasound evaluation included bilateral detection and scoring of synovitis (3 joints, 0-3), tenosynovitis (flexor tendons, 0-3), enthesitis (9 sites, 0-1), peri‑extensor tendon inflammation (PETI) (0-3), and subcutaneous tissue inflammation (SCTI) (0-3) in the 2nd-5th fingers.
Results: Seventy patients [44 women; mean (SD) age 51 (12.4) years] were included, of whom 64 completed the study. Of these, 15 (23.4 %) were diagnosed with PsA during the 12-month follow-up period. At finger level, the presence and amount of baseline BM and PD synovitis, BM tenosynovitis, BM and PD enthesitis, and BM and PD PETI were associated with PsA diagnosis (p < .05). A predictive model including two variables, presence of PD synovitis and BM enthesitis, was found to predict PsA diagnosis (χ2 = 35.38; p < .001) with an accuracy of 89.1 %, a sensitivity of 86.7 % and a specificity of 89.8 %.
Conclusions: Ultrasound-assessed lesions of dactylitis were associated with a diagnosis of PsA and the short-term development of PsA in patients with PsO and hand arthralgia.
Keywords: Dactylitis; Enthesitis; Psoriasis; Psoriatic arthritis; Ultrasound.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Otto Olivas-Vergara: Speaker fees from UCB Pharma. Lina Martínez-Estupiñán: Currently is employee of Abbvie. Fredeswinda Romero-Bueno: None. Olga Sanchez-Pernaute: None. Javier R. Godo: None. Maria del Carmen Fariña Sabaris: Speaker fees from Almirall, Abbvie, Novartis, Janssen, UCB Pharma, Amgen, Lilly. Belen Ruffin Vicente: None. Agustina Criado Alcazar: None. Pablo E. Borges: None. Sheila Recuero-Díaz: None. Andrea Alvear-Torres: None. Amalia Gil: None. Antía García-Fernández: None. Ana Elena Hoyo Fernández: None. M. Belen Ortega Trompeta: None. M. Isabel Sanchez-Barba Izquierdo: None. Gabriel Herrero-Beaumont: None. Raquel Largo: None. Esperanza Naredo: Speaker fees from Novartis; Research grant from Lilly and Abbvie.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous